StockNews.com upgraded shares of Kamada (NASDAQ:KMDA – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. Separately, HC Wainwright restated a “buy” rating and ...
Operator: Greetings, and welcome to the Kamada Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time all ...
8d
Kamada Ltd (KMDA) reports a 13% revenue increase and unveils plans for biosimilar launches and plasma center expansions.
Record Year with Total 2024 Revenues of $161.0 Million, Representing a 13% Increase over Fiscal Year 2023 and Adjusted EBITDA of $34.1 Million, Up 42% Year-over-Year, and a 21% Margin of RevenuesCash ...
Proposed changes to this list are open for consultation. Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback